Whalesbook
Sanjivani Paranteral Limited has released its audited financial results for the fiscal year ending March 31, 2026. The company reported a standalone net profit of ₹6.92 crore on revenue of ₹66.00 crore for the full year. Consolidated figures for FY26 showed a net profit of ₹6.69 crore on revenue of ₹68.67 crore.
The fourth quarter (Q4 FY26) faced challenges, with standalone revenue at ₹10.51 crore and profit at ₹0.94 crore. Consolidated Q4 revenue was ₹13.21 crore, yielding a profit of ₹0.55 crore.
Prague Plant Begins Shipments, Expanding Global Reach
A key operational highlight for the year was the commencement of shipments from the company's new plant in Prague. This international expansion effort contributed approximately USD 0.5 million in its initial phase. Alongside this, Sanjivani Paranteral's Pune IV fluids plant is undergoing a gradual scale-up, with the company focusing on securing necessary approvals and registrations to enhance its capacity utilization.
Logistical Hurdles Impact Q4 Performance
The company's performance in the fourth quarter was significantly affected by external factors. Temporary logistical disruptions in export markets led to shipment delays. Furthermore, geopolitical tensions resulted in approximately ₹6 crore worth of finished goods being held back from dispatch in March 2026. These issues impacted revenue realization and profit margins for the quarter, highlighting current supply chain vulnerabilities.
Company Overview and Strategic Growth
Sanjivani Paranteral is an Indian pharmaceutical manufacturer specializing in intravenous (IV) fluids. The company has strategically focused on expanding its manufacturing capabilities, including its Pune facility. The establishment and recent operational start of the Prague plant mark a significant step in its international growth strategy.
Investor Focus: Future Growth and Risk Mitigation
The beginning of shipments from the Prague plant is anticipated to contribute positively to Sanjivani Paranteral's overall profitability and expand its global footprint. Improving capacity utilization at the Pune plant is also crucial for enhancing domestic operational efficiency. Investors will closely monitor how effectively the company navigates ongoing logistical and geopolitical challenges to maintain its growth trajectory. Future expansion plans and the company's ability to improve EBITDA margins despite operational factors will also be key points of attention.
Industry Peers in Injectables
Sanjivani Paranteral operates within the IV fluids segment. In the broader injectables and pharmaceutical sector, key companies like Gland Pharma and Strides Pharma Science are larger and more diversified. Baxter India, a multinational competitor, also competes in similar product categories. This positions Sanjivani Paranteral as a more specialized domestic player with a growing international presence.